,,iii  #aaf? ,,congress  #a/ ,session   
,s4 ,,res4 #bde  ,,9 ,,! ,,s5ate ,,( ,,!
 ,,unit$ ,,/ates  ,june #aa1 #bjai ,mr4 
,graham 7= himself1 ,ms4 ,mc,sally1 ,ms4
 ,s9ema1 ,ms4 ,w>r51 ,mr4 ,mc,connell1 &
 ,mr4 ,m>key7 submitt$ ! foll[+         
resolution2 :i* 0 consid]$ & agre$ to   
,,resolution  ,designat+ ,july #ag1     
#bjai1 z ,gliobla/oma ,aw>5ess ,day4    
,:]eas an e/imat$ #ac1caj new cases (   
gliobla/oma w be diagnos$ 9 ! ,unit$    
,/ates 9 #bjai2 ,:]eas gliobla/oma is-- 
7#a7 ! mo/ common malignant 7canc]\s7   
bra9 tumor1 acc\nt+ = #dg p]c5t ( all   
prim>y malignant bra9 tumors2 &  7#b7 ! 
mo/ aggressive1 complex1 difficult to   
treat1 & deadlie/ bra9 tumor2 ,:]eas x  
is e/imat$ t m ?an #ae1jjj p 9 ! ,unit$ 
,/ates w succumb to gliobla/oma e ye>2  
,:]eas ! #e-ye> survival rate =         
gliobla/oma pati5ts is only #e4f p]c5t &
 ! av]age survival = gliobla/oma pati5ts
 is e/imat$ to be only #ab to #ah mon?s2
 ,:]eas gliobla/oma is describ$ z a     
disease t affects ! ess5ce ( self1 z !  

treatm5t & removal ( gliobla/oma pres5ts
 significant *all5ges because ( !       
uniquely complex & fragile nature ( !   
bra91 ! prim>y organ 9 ! human body t   
controls n only cognitive ability1 b !  
actions ( e organ & limb2 ,:]eas bra9   
canc] has-- 7#a7 ! highe/ p]-pati5t     
initial co/ ( c>e = any canc] gr\p1 ) an
 annualiz$ mean net co/ ( c>e approa*+  
#aej1jjj2 &  7#b7 ! highe/ annualiz$    
mean net co/s = la/-ye>-(-life c>e1     
relative to o!r canc]s1 at #ace1jjj to  
#baj1jjj 7dep5d+ on age & g5d]7 p]      
pati5t2  ,:]eas1 al?\gh rese>* advances 
may fuel ! developm5t ( new treatm5ts = 
gliobla/oma1 *all5g+ ob/acles to        
accel]at+ progress t[>d new treatm5ts = 
gliobla/oma rema91 & !re are no scre5+  
or e>ly detection me?ods2 ,:]eas1 al?\gh
 gliobla/oma 0 fir/ describ$ 9 m$ical & 
sci5tific lit]ature 9 ! #aibjs1 &       
despite its deva/at+ prognosis1 only #d 
drugs & #a m$ical device h be5 approv$  
by ! ,food & ,drug ,adm9i/ration to     
treat gliobla/oma s9ce ! #aibjs1 & !    

mortality rates associat$ ) gliobla/oma 
h *ang$ little dur+ ! pa/ #cj ye>s2 &   
,:]eas !re is a ne$ = great] public     
aw>5ess ( gliobla/oma1 includ+ bo? !    
urg5t unmet m$ical ne$1 z well z !      
opportunities = rese>* & treatm5t       
advances = gliobla/oma pati5ts3 ,n[1    
!re=e1 be x  ,t ! ,s5ate-- 7#a7         
designates ,july #ag1 #bjai1 z          
,gliobla/oma ,aw>5ess ,day2  7#b7       
enc\rages increas$ public aw>5ess (     
gliobla/oma2  7#c7 honors ^? individuals
 :o h lo/ _! lives to t deva/at+ disease
 or are curr5tly liv+ ) x2  7#d7        
supports ef=ts to develop bett]         
treatm5ts = gliobla/oma t w improve !   
long-t]m prognosis ( individuals        
diagnos$ ) gliobla/oma2  7#e7 expresses 
its support = ^? individuals :o are     
battl+ bra9 tumors1 z well z ! families1
 fri5ds1 & c>egiv]s ( ^? individuals2 & 
7#f7 urges a collaborative approa* to   
bra9 tumor rese>*1 :i* is a promis+     
means ( advanc+ und]/&+ (1 & treatm5t =1
 gliobla/oma4